The Food and Drug Administration ( FDA ) has approved Osimertinib ( Tagrisso ) for the first-line treatment of patients with metastatic non-small cell lung cancer ( NSCLC ) whose tumors have epidermal growth factor receptor ( EGFR ) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Approval was based on a multicenter, international, randomized, double-blind, active-controlled trial ( FLAURA ) conducted in 556 patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive, unresectable or metastatic NSCLC who had not received previous systemic treatment for advanced disease.
Patients were randomized ( 1:1 ) to receive Osimertinib 80 mg orally once daily or standard-of-care ( SOC ) treatment of Gefitinib 250 mg or Erlotinib 150 mg orally once daily.
Of those randomized to SOC, 20% received Osimertinib as the next line of antineoplastic therapy.
The estimated median progression-free survival ( PFS ) was 18.9 months ( 95% CI: 15.2, 21.4 ) in the Osimertinib arm and 10.2 months ( 95% CI: 9.6, 11.1 ) in the SOC arm ( hazard ratio, HR=0.46; 95% CI: 0.37, 0.57; p less than 0.0001 ).
The confirmed overall response rate ( ORR ) was 77% for the Osimertinib arm and 69% for the SOC arm.
The estimated median response durations for the Osimertinib and SOC arms were 17.6 and 9.6 months, respectively.
At the time of the primary PFS analysis, there were too few deaths to estimate or compare survival outcomes.
The most common adverse reactions ( occurring in at least 20% of patients treated with Osimertinib ) were diarrhea, rash, dry skin, nail toxicity, stomatitis, and decreased appetite.
Serious adverse reactions were reported in 4% of patients treated with Osimertinib.
The most common serious adverse reactions ( greater than or equal to 1% ) were pneumonia ( 2.9% ), ILD/pneumonitis ( 2.1% ), and pulmonary embolism ( 1.8% ).
The recommended dose of Osimertinib is 80 mg orally once daily, with or without food. ( Xagena )
Source: FDA, 2018